About 17 results found for searched term "PKG" (0.218 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14756 | PKG drug G1 | Others |
| PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism. | ||
| M53890 | PKG inhibitor peptide | PKG |
| PKG inhibitor peptide is an ATP-competitive inhibitor of cGMP-dependent protein kinase (PKG), with a Ki of 86 μM. | ||
| M54487 | PKG Substrate | PKG |
| PKG Substrate is a selective substrate for cGMP-dependent protein kinase (PKG). | ||
| M2066 | Staurosporine | PKC |
| AM-2282; STS; CGP 41251 | ||
| Staurosporine (AM-2282) is a potent ATP-competitive kinase inhibitor with IC50 of 0.7, 7, 8.5, 6, 20 nM for PKC, PKA,PKG, p60v-src tyrosine protein kinase, CaM kinase II, respectively. | ||
| M3559 | H-89 | PKA |
| Protein kinase inhibitor H-89 | ||
| H-89 is a potent PKA inhibitor with Ki of 48 nM, 10-fold selective for PKA than PKG, greater than 500-fold selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. | ||
| M3607 | Fasudil | ROCK |
| AT-877; HA-1077 | ||
| Fasudil (HA-1077) is a potent inhibitor of ROCK-II, PKA, PKG, PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively. | ||
| M22480 | 8-Bromo-cGMP sodium | Calcium Channel |
| 8-Bromo-cGMP sodium is a PKG (protein kinase G) activator, it is a membrane-permeable analogue of cGMP. 8-Bromo-cGMP sodium significantly inhibits Ca2+ macroscopic currents and impairs insulin release stimulated with high K+. | ||
| M6552 | HA-100 | PKA |
| C-1 | ||
| Ha-100 is a potent protein kinase inhibitor with IC50 values of 4 μM, 8 μM, 12 μM and 240 μM against PKG, PKA, PKC and MLC kinases, respectively. Ha-100 is also used as a ROCK inhibitor. | ||
| M7215 | Rp-8-pCPT-cGMPS sodium | PKG |
| Rp-8-pCPT-cGMPS sodium is a pKG inhibitor. | ||
| M7870 | KT5823 | PKA |
| KT-5823 | ||
| KT5823 is a selective the cGMP-dependent protein kinase (PKG) inhibitor with an Ki value of 0.23 μM, it also inhibits PKA and PKC with Ki values of 10 μM and 4 μM, respectively. | ||
| M7998 | PET-cGMP | Others |
| cGMP-dependent protein kinase (PKG I and PKG II) activator. | ||
| M8585 | Rp-8-Br-cGMPS sodium salt | Others |
| Rp-8-bromo-cGMPS is a cell permeable cGMP analog that blocks cGMP-dependent protein kinase (cGK, G-kinase, Protein Kinase G, PKG). | ||
| M20716 | MBP146-78 | Others |
| MBP146-78 is a potent and selective inhibitor of cyclic GMP(cGMP)-dependent protein kinases/Protein Kinase G (PKG) and displays cytostatic activity against Toxoplasma gondii. | ||
| M20755 | HA-100 dihydrochloride | PKC |
| HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively. | ||
| M43069 | SMA4 | Others |
| SMA4 is a selective PKG1α activator with basal EC50 value of 29 μM. | ||
| M50448 | DT-2 | Others |
| DT-2 is a potent and selective inhibitor of the cGMP-dependent protein kinase (PKG). | ||
| M55306 | Guanosine 3′,5′-cyclic monophosphate | Others |
| cGMP | ||
| Guanosine 3′,5′-cyclic monophosphate (cGMP) acts as an important second messenger, cGMP is a major intracellular mediator of extracellular signals such as nitric oxide and natriuretic peptides. Cyclic GMP interacts with three types of intracellular receptor proteins: cGMP-dependent protein kinases, cGMP-regulated channels, and cGMP-regulated cyclic nucleotide phosphodiesterases. A primary action of elevated cGMP levels in vivo is the stimulation of cGMP-dependent protein kinase (PKG). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
